Fuller & Thaler Asset Management
BIO icon

Fuller & Thaler Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Fuller & Thaler Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-259,577
Closed -$78.6M – 501
2025
Q4 		$78.6M Buy
259,577
+21,674
+9% +$6.76M 0.27% 141
2025
Q3 		$66.7M Buy
+237,903
New +$64.7M 0.23% 163
2015
Q1 		– Sell
-500
Closed -$60K – 653
2014
Q4 		$60K Sell
500
-200
-29% -$23K ﹤0.01% 558
2014
Q3 		$79K Buy
+700
New +$82.9K ﹤0.01% 572

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fuller & Thaler Asset Management's BIO Position: Q1 2026 in Review

Fuller & Thaler Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 259,577 shares — an estimated $78.6M sold.

Fuller & Thaler Asset Management first reported a position in BIO in Q3 2014 and held it in 4 quarters. The position peaked at $78.6M in Q4 2025. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Fuller & Thaler Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 259,577 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $78.6M.
  • Fuller & Thaler Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2014 and held it in 4 quarters.
  • Fuller & Thaler Asset Management's Bio-Rad Laboratories Class A position peaked at $78.6M in Q4 2025.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q1 2026, filed 14 May 2026.